Clay Thorp Executive Chairman
Since 1995, Clay has co-founded seven companies in the life science arena including PhaseBio Pharmaceuticals. He also co-founded Hatteras Venture Partners in 2000, and has been instrumental in building the firm from its origins with a $3 million seed fund to a venture capital partnership that manages over $350 million across five funds. Clay was co-founder, CEO and Chairman of Synthematix, Inc., a chemistry informatics company acquired in April 2005 by Symyx Technologies (SMMX). He was the co-founder and head of corporate development for Novalon Pharmaceutical Corporation, where he led financing efforts and was head of business development from inception until Novalon’s sale to Karo Bio for $106.7 million in May of 2000. Prior to Novalon, Clay was the co-founder and president of Xanthon, Inc., a bioinformatics company with electro-chemical detection technology for direct analysis of DNA, RNA and proteins. Clay currently serves as Chairman of GeneCentric Diagnostics and is on the boards of Clearside Biomedical, Curoverse, Lysosomal Therapeutics, and Orig3n. He holds a Masters of Public Policy from Harvard University and a B.A. in mathematics and art history from the University of North Carolina at Chapel Hill.
James Barrett, PhD
Jim joined New Enterprise Associates (NEA) in 2001 as a general partner. Specializing in biotechnology, he works with members of NEA’s healthcare investment group on medical devices, healthcare information systems and healthcare service companies. Prior to joining NEA, Jim served as founder, chairman and chief executive officer of Sensors for Medicine and Science, where he remains chairman. In addition to PhaseBio, Jim currently serves on the boards of directors at several other biotechnology and pharmaceutical companies.
Ashutosh Chilkoti, PhD
Ashutosh is a co-founder of PhaseBio, a professor in the biomedical engineering department at Duke University. His research in biomolecular materials and surface science emphasizes the development of applications that span the range from bioseparations, biosensors, patterned biomaterials and targeted drug delivery. Ashutosh invented PhaseBio’s drug delivery technology and serves as the company’s scientific advisor in protein purification and drug delivery.
Guy Fish, MD
Guy joined Fletcher Spaght Ventures in 2002 and is vice president in the healthcare practice group. Previously a practicing internist, Guy held an operating position at Collagenesis, was a senior member of The Boston Consulting Group and served as a securities analyst in the medical devices group of Sanford C. Bernstein and Co. Guy serves on the boards of directors of several other life sciences companies and maintains an active consulting practice at Fletcher Spaght, Inc., where he advises start-ups seeking pre-commercialization intelligence and large corporations seeking diligence.
Bob has been a general partner at Hatteras Venture Partners since 2004. Prior to Hatteras, he had a long and distinguished career in pharmaceuticals, most recently as chief executive officer and chairman of GlaxoWellcome. There he co-led the merger and integration that formed GlaxoSmithKline (GSK). Bob sits on the boards of directors at several corporations, including Valeant Pharmaceuticals, Regeneron, CREE and BioCryst.
Justin Klein, MD, JD
Justin joined NEA in 2006 and is a Partner on the healthcare team. He focuses on medical device, healthcare technology, and biopharmaceutical company investments. He serves as a director of Advanced Cardiac Therapeutics, Cartiva, FIRE1, Intact Vascular, PhaseBio Pharmaceuticals, Relievant Medsystems, Senseonics, VertiFlex, and VytronUS. Justin’s past board memberships and investments include CV Ingenuity (acquired by Covidien), Nevro (NYSE: NVRO), Topera (acquired by Abbott), TriVascular (NASDAQ: TRIV), and Ulthera (acquired by Merz). He is also a member of the advisory boards for the National Venture Capital Association’s Medical Industry Group and its Medical Innovation and Competitiveness Coalition (MedIC), as well as a member of AdvaMed’s Business Development Committee. Prior to NEA, Justin worked for the Duke University Health System, reporting directly to the hospital CEO on health system strategy, finance and clinical service unit operations. Justin has an AB in Economics and a BS in Biological Anthropology and Anatomy from Duke University, an MD from the Duke University School of Medicine and a JD from Harvard Law School.
Han Lee, PhD
Han Lee is currently a Senior Director within AstraZeneca’s Corporate Development and Ventures group, having responsibility for mergers and acquisitions, transformative deals, and strategic equity investments. Prior to AstraZeneca, Han was an integral part of two biotech start-ups that both had successful exits and was a part of entrepreneurial teams that raised over $100 million. Han received his BA in Genetics and minor in Chemistry from the University of California, Berkeley. He received his PhD in Genetics and his MBA from Yale University.
Jonathan is a life sciences executive with more than 25 years of experience in biotechnology management. He is chief executive officer of PhaseBio, and previously served as the company’s chief business officer. Prior to PhaseBio, Jonathan served as vice president, business development for Amylin Pharmaceuticals from 2007 until its sale to Bristol-Myers Squibb in 2012. Jonathan was co-founder and vice president, commercial and business development of Corus Pharma, Inc. until its acquisition by Gilead Sciences in 2006. Earlier in his career, he led the business development efforts for PathoGenesis Corporation, culminating in the company’s acquisition by Chiron Corporation in 2000. Jonathan has held positions in sales and marketing at Bristol-Myers Squibb, Wyeth / Lederle International and Syntex Laboratories. Jonathan holds a BS in Mechanical Engineering from UC Berkeley and an MBA from Carnegie Mellon University Tepper School of Business.
Marian Nakada, PhD
Marian is Vice President, Venture Investments at Johnson & Johnson Innovation – JJDC Inc., the corporate venture arm of Johnson & Johnson. She is based in the Boston Innovation Center and focuses on investments in East Coast companies in areas of strategic interest to Janssen R&D. Marian previously held roles at Centocor R&D, Janssen R&D, and Janssen Business Development. She has a BA in Biology from Harvard College and a PhD in Pharmacology from the University of Pennsylvania. Marian was the JJDC investor for CoStim Pharmaceuticals, Vedanta Biosciences, Rodin Therapeutics, and Padlock Therapeutics and currently also sits on the Boards of Navitor Pharmaceuticals and the New England Venture Capital Association.